Berlin (Germany) and San Diego, CA (U.S.A.), November 15, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that Dr. Medhi Najafzadeh, PhD and Dr. Elvira D’Andrea, MD, MPH, two of the lead authors of the microsimulation model comparing outcomes of colorectal cancer screening methods, including the Epi proColon® blood test, will participate in a conference call on November 21, 2019 at 3pm CET. Dr. Najafzadeh and Dr. D’Andrea, both from the Division of Pharmacoepidemiology and Pharmacoeconomics at Harvard Medical School, will discuss Dr. D‘Andrea’s conference presentation entitled “Quantifying the impact of adherence to screening on colorectal cancer incidence and mortality” at the upcoming European Public Health conference. Investors are invited to participate via Webcast.
The Webcast can be accessed in the investor relations section of the Epigenomic‘s website at www.epigenomics.com/news-investors/. The dial-in numbers will be published in the financial calendar in the coming week.
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung®, a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.
For more information, visit www.epigenomics.com.
Epigenomics AG, Investor Relations, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30
24345 386, Fax +49 (0) 30 24345 555, E-Mail: email@example.com
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: firstname.lastname@example.org
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.